Want to see HK:2196 full AI Analyst Report?
Top Page
Shanghai Fosun Pharmaceutical (Group) Co
(2196)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$17.00
â–˛(2.66% Upside)
Action:Reiterated
Date:09/06/26
The score is driven mainly by improving financial performance (strong TTM revenue rebound and stable margins) but capped by higher leverage and uneven free cash flow. Technical indicators are the key drag, with the stock trading below major moving averages and negative MACD. Valuation is supportive but only moderately so given the P/E and dividend yield.
Positive Factors
Revenue rebound
The strong TTM revenue rebound indicates improving demand, pricing, or product mix after several weaker years. If sustained, renewed top-line growth can expand the company’s commercial scale, support fixed-cost absorption, and provide a stronger base for investment across its pharmaceutical businesses.
Negative Factors
Rising leverage
The increase in debt-to-equity shows that expansion is relying more heavily on borrowing while equity remains relatively stable. Higher leverage reduces financial flexibility, increases the importance of dependable cash generation, and can constrain future investment or shareholder-return choices.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The strong TTM revenue rebound indicates improving demand, pricing, or product mix after several weaker years. If sustained, renewed top-line growth can expand the company’s commercial scale, support fixed-cost absorption, and provide a stronger base for investment across its pharmaceutical businesses.
Read all positive factors
Shanghai Fosun Pharmaceutical (Group) Co (2196) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$64.20B
Dividend Yield2.78%
Average Volume (3M)3.67M
Price to Earnings (P/E)17.5
Beta (1Y)1.13
Revenue Growth9.88%
EPS Growth9.30%
CountryHK
Employees40,603
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.90
Shares Outstanding551,940,500
10 Day Avg. Volume4,769,813
30 Day Avg. Volume3,673,685
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$22.45Price Target Upside35.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.44
Revenue Forecast (FY)HK$42.83B
Shanghai Fosun Pharmaceutical (Group) Co Business Overview & Revenue Model
Company Description
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of p...
How the Company Makes Money
Fosun Pharma generates revenue primarily through a multi-segment model: (1) Pharmaceutical manufacturing and commercialization: the company earns product sales revenue by selling proprietary and partnered pharmaceutical products to hospitals, phar...
Shanghai Fosun Pharmaceutical (Group) Co Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
66
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.75B | 40.42B | 41.07B | 41.40B | 43.95B | 39.01B |
| Gross Profit | 30.96B | 20.16B | 19.70B | 19.68B | 20.78B | 18.78B |
| EBITDA | 7.41B | 6.16B | 8.60B | 7.55B | 7.87B | 8.70B |
| Net Income | 5.03B | 3.28B | 2.77B | 2.39B | 3.73B | 4.73B |
Balance Sheet | ||||||
| Total Assets | 125.37B | 120.07B | 117.46B | 113.47B | 107.16B | 93.29B |
| Cash, Cash Equivalents and Short-Term Investments | 16.31B | 15.78B | 16.12B | 15.58B | 17.17B | 14.55B |
| Total Debt | 39.45B | 36.66B | 31.70B | 30.28B | 30.25B | 24.25B |
| Total Liabilities | 62.01B | 58.24B | 57.53B | 56.85B | 53.05B | 44.92B |
| Stockholders Equity | 48.68B | 48.72B | 47.26B | 45.68B | 44.58B | 39.19B |
Cash Flow | ||||||
| Free Cash Flow | 699.77M | 764.78M | 66.79M | -1.92B | -1.67B | -1.02B |
| Operating Cash Flow | 5.50B | 5.21B | 4.48B | 3.41B | 4.22B | 3.95B |
| Investing Cash Flow | -5.71B | -2.15B | -3.61B | -3.82B | -4.06B | -3.86B |
| Financing Cash Flow | 892.11M | -3.24B | -1.00B | -1.34B | 4.43B | -831.28M |
Shanghai Fosun Pharmaceutical (Group) Co Technical Analysis
Negative
16.56
Price Trends
16.38
Negative
16.90
Negative
18.45
Negative
Market Momentum
-0.12
Positive
45.90
Neutral
18.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2196, the sentiment is Negative. The current price of 16.56 is below the 20-day moving average (MA) of 16.73, above the 50-day MA of 16.38, and below the 200-day MA of 18.45, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 45.90 is Neutral, neither overbought nor oversold. The STOCH value of 18.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2196.
Shanghai Fosun Pharmaceutical (Group) Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$219.76B | 28.15 | 18.26% | 1.34% | 24.97% | 43.23% | |
69 Neutral | HK$24.50B | 14.16 | 11.97% | 8.06% | -5.90% | -18.84% | |
68 Neutral | HK$27.86B | 5.91 | 7.92% | 5.40% | 7.94% | 52.83% | |
61 Neutral | HK$26.93B | 15.22 | 8.60% | 3.12% | 14.80% | -2.88% | |
59 Neutral | HK$64.20B | 17.45 | 6.97% | 2.78% | 9.88% | 9.30% | |
59 Neutral | HK$36.22B | 12.81 | 6.64% | 6.39% | 6.58% | -4.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
16.20
-9.54
-37.06%
HK:0867
China Medical System Holdings
11.04
-2.94
-21.02%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
13.51
-4.07
-23.14%
HK:1513
Livzon Pharmaceutical Group
20.38
-15.52
-43.23%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.44
-0.28
-5.98%
HK:3692
Hansoh Pharmaceutical Group Company Limited
36.24
-1.49
-3.94%
Shanghai Fosun Pharmaceutical (Group) Co Corporate Events
Fosun Pharma Wins China Approval for New Luvometinib Indication
Sep 3, 2026
Shanghai Fosun Pharmaceutical said its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development, has received approval from China’s National Medical Products Administration for an additional indication of its Luvometinib Tablets. The...
Fosun Pharma Grants Reserved A Share Options Under 2025 Incentive Scheme
Aug 28, 2026
Shanghai Fosun Pharmaceutical has approved a reserved grant of 725,100 A share options under its 2025 A Share Option Scheme, representing about 0.0272% of its total share capital, to 100 participants at an exercise price of RMB27.93 per share. Som...
Fosun Pharma Grants New H Share RSUs to 100 Employees Under 2025 Incentive Scheme
Aug 28, 2026
Shanghai Fosun Pharmaceutical has approved a reserved grant of 1,695,400 H share–linked restricted share units to 100 eligible employees under its 2025 H Share RSU Scheme, representing about 0.3135% of its outstanding H shares. The award, gr...
Fosun Pharma Unit Secures Exclusive Rights to Advanced Bispecific Antibody Drug
Aug 27, 2026
Shanghai Fosun Pharmaceutical has announced that its subsidiary Yao Pharmaceutical Company Limited has secured exclusive rights from Chongqing Genrix Biopharmaceutical to develop and commercialize a bispecific antibody drug using GR1803, which tar...
Shanghai Fosun Pharma Executes HK$3.6 Million H-Share Buyback
Aug 27, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has used its shareholder-approved H share repurchase mandate to buy back 217,000 H shares on the open market on 27 August 2026. The shares were repurchased at an average price of HKD16.53, for a tota...
Fosun Pharma Posts Modest Profit Growth in First-Half 2026 Results
Aug 25, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a major China-based healthcare and pharmaceutical group listed in Hong Kong, reported unaudited interim results for the six months ended 30 June 2026. The company continues to derive revenue from a ...
Fosun Pharma Subsidiary Advances COPD Drug FXS7553 Into Phase II Trial in China
Aug 13, 2026
Shanghai Fosun Pharmaceutical has announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development, has initiated a Phase II clinical trial in China for FXS7553, an orally administered small-molecule DPP-1 inhibitor targeting ch...
Fosun Pharma Sets August Board Meeting to Approve 2026 Interim Results
Aug 13, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has scheduled a board meeting for 25 August 2026 to review and approve the group’s interim results for the six months ended 30 June 2026. The company plans to publish these interim results foll...
Fosun Pharma Wins NMPA Approval for New Levosalbutamol Nebuliser Therapy
Aug 7, 2026
Shanghai Fosun Pharmaceutical has announced that its subsidiary Fosun Pharma (Xuzhou) has received approval from China’s National Medical Products Administration for its Levosalbutamol Hydrochloride Nebuliser Solution. The product is indicat...
Fosun Pharma Subsidiary Wins China Approval for Heart Failure Injection
Aug 7, 2026
Shanghai Fosun Pharmaceutical said its subsidiary Shanghai Zhaohui Pharmaceutical has received approval from China’s National Medical Products Administration for its Dobutamine Hydrochloride Injection. The product is indicated for short-term...
Fosun Pharma Subsidiary Wins Approval for Pediatric Constipation Drug in China
Aug 3, 2026
Shanghai Fosun Pharmaceutical’s subsidiary Suzhou Erye Pharmaceutical has received approval from China’s National Medical Products Administration for its Polyethylene Glycol (3350) and Electrolytes Powder. The drug is indicated for tre...
Fosun Pharma Subsidiary Wins Approval for New Type 2 Diabetes Combination Drug
Aug 3, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group has received approval from China’s National Medical Products Administration for Empagliflozin and Metformin Hydrochlor...
Fosun Pharma Unit Wins NMPA Nod for Parkinson’s Drug Trial
Jul 24, 2026
Shanghai Fosun Pharmaceutical said its subsidiary Fosun Wanbang has received approval from China’s National Medical Products Administration to begin clinical trials of DM1001, a chemical drug candidate for treating the signs and symptoms of ...
Fosun Pharma Wins NMPA Nod for FXR0906 Hypertriglyceridemia Trial
Jul 15, 2026
Shanghai Fosun Pharmaceutical’s subsidiary Fosun Pharmaceutical Industrial Development (Shenzhen) has obtained approval from China’s National Medical Products Administration to begin clinical trials of FXR0906, a liver-targeted siRNA t...
Fosun Pharma Subsidiary Wins Approval for New Traditional Chinese Medicine Granules
Jun 29, 2026
Shanghai Fosun Pharmaceutical said its subsidiary Hebei Wanbang Folon Pharmaceutical has received approval from China’s National Medical Products Administration for Shaoyao Gancao Tang Granules, a Class 3.1 traditional Chinese medicine. The ...
Fosun Pharma Moves Ahead With Spin-Off Listing of Fosun Adgenvax in Hong Kong
Jun 26, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. plans to spin off its subsidiary Fosun Adgenvax for a separate listing of H shares on the Main Board of the Hong Kong Stock Exchange, while retaining it as a subsidiary. The proposed issuance will in...
Fosun Pharma Shareholders Back AGM Resolutions and Final Dividend
Jun 16, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a major Chinese pharmaceutical and healthcare group listed in both A-share and H-share markets, held its annual general meeting and separate class meetings for A and H shareholders in Shanghai on 16...
Fosun Pharma Sets Final 2025 Dividend and Withholding Tax Terms for H-Share Investors
Jun 16, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has declared a final ordinary cash dividend of RMB 0.39 per share for the financial year ended 31 December 2025, with approval obtained on 16 June 2026. For H-share holders registered in Hong Kong, t...
Fosun Pharma Wins NMPA Approval for New Pediatric Use of Luvometinib
Jun 15, 2026
Shanghai Fosun Pharmaceutical has announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development, has received approval from China’s National Medical Products Administration for an additional indication of its drug Luvom...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.